Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of Rituximab and Tafasitamab with allogeneic NK cells in relapsed/refractory B-cell non-Hodgkin lymphoma; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Allogeneic natural killer cells
• Rituximab (rituximab)
• tafasitamab (tafasitamab)

Snippet

Sponsor: Paolo Caimi, MD | Conditions: Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING